menu
    • menu
    [{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Manhattan BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Recombinant Mycobacterium Bovis Bacillus Calmette-Guerin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Nascent Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Nascent Biotech"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Hoag Memorial Hospital Presbyterian","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nascent Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Hoag Memorial Hospital Presbyterian","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nascent Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"HypoSpray Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nascent Biotech \/ Nascent Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Nascent Biotech"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Nascent Biotech

    Menu

    Nascent Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : HypoSpray Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nascent Biotech & HypoSpray Pharma Collaborate on Proprietary Transdermal Delivery System

                            Details : The collaboration aims to develop an alternative delivery mechanism for patients who can benefit from ACA-11 (pritumumab), Nascent's lead monoclonal antibody cancer treatment asset, for Brain Cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 19, 2024

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : HypoSpray Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

                            Details : Pritumumab is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 13, 2022

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain...

                            Details : PTB is a natural human antibody that works by binding to Cell surface Vimentin (also referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 08, 2021

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Hoag Memorial Hospital Presbyterian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastati...

                            Details : Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Company’s lead Monoclonal Antibody (Mab) therapeutic asset, as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 24, 2021

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Hoag Memorial Hospital Presbyterian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nascent Biotech Appoints Chief Medical Consultant in Charge of COVID-19 Research

                            Details : Nascent Biotech appointed Dr. Navpaul Singh MD as Chief Medical Consultant in charge of research into Pritumumab’s use with viral infections, including COVID-19.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 24, 2020

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Hoag Memorial Hospital Presbyterian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of Pritumumab in Brain Cancer

                            Details : Pritumumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 21, 2020

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Hoag Memorial Hospital Presbyterian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Mycobacterium Bovis Bacillus Calmette-Guerin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Manhattan BioSolutions

                            Deal Size : $0.2 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Developme...

                            Details : Research Collaboration Agreement to initiate a vaccine program for the potential prevention of COVID-19 or other viral infections. This effort will augment Nascent’s current development plants to investigate the utility of Pritumumab for the treatment ...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : $0.1 million

                            May 12, 2020

                            Lead Product(s) : Recombinant Mycobacterium Bovis Bacillus Calmette-Guerin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Manhattan BioSolutions

                            Deal Size : $0.2 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nascent Biotech Provides Update on its Antibody Therapy for COVID-19 and also Human Brain Cancer Trials

                            Details : Nascent has initiated tests to assess its monoclonal antibody Pritumumab (PTB) against the novel coronavirus. Also, finalizing the human brain cancer trial’s timeline with help of a CRO.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 22, 2020

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nascent Biotech

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nascent Biotech Investigation Drug Product, Pritumumab, to be Studied as a Therapeutic agent against Covid-19

                            Details : Pritumumab, the lead asset of Nascent which targets cell surface vimentin, will be studied as a potential therapeutic agent against (Coronavirus) Covid-19.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 03, 2020

                            Lead Product(s) : Pritumumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.